<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04608513</url>
  </required_header>
  <id_info>
    <org_study_id>ID-087-102</org_study_id>
    <nct_id>NCT04608513</nct_id>
  </id_info>
  <brief_title>A Placebo-controlled Phase 1 Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Single- and Multiple-ascending Doses of ACT-1014-6470 in Healthy Subjects</brief_title>
  <official_title>A Single-center, Double-blind, Randomized, Placebo-controlled Phase 1 Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Single- and Multiple-ascending Doses of ACT-1014-6470 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Idorsia Pharmaceuticals Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Idorsia Pharmaceuticals Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A safety and tolerability study in healthy subjects including examination of how the body&#xD;
      takes up, distributes, and gets rid of ACT-1014-6470&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 16, 2020</start_date>
  <completion_date type="Actual">September 20, 2021</completion_date>
  <primary_completion_date type="Actual">September 20, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Single-center, double-blind, randomized, placebo-controlled, single- and multiple-ascending dose</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety profile including incidence of treatment-emergent adverse events.</measure>
    <time_frame>Safety and tolerability assessments will be performed at predefined time points from Day 1 to Day 4 in Part A and Day 1 to Day 10 in Part B (total duration: max. 50 days).</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part A - Single ascending dose (SAD): Area under the plasma concentration-time curve (AUC) from zero to time t of the last measured concentration above the limit of quantification (AUC0-t).</measure>
    <time_frame>Blood samples for the determination of the PK parameters will be collected at predefined time points from Day 1 to Day 4 (total duration: max. 4 days).</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A - Single ascending dose (SAD): Area under the plasma concentration-time curve (AUC) from zero to infinity (AUC0-inf).</measure>
    <time_frame>Blood samples for the determination of the PK parameters will be collected at predefined time points from Day 1 to Day 4 (total duration: max. 4 days).</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A - Single ascending dose (SAD): Maximum plasma concentration (Cmax).</measure>
    <time_frame>Blood samples for the determination of the PK parameters will be collected at predefined time points from Day 1 to Day 4 (total duration: max. 4 days).</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A - Single ascending dose (SAD): Time to reach Cmax (tmax).</measure>
    <time_frame>Blood samples for the determination of the PK parameters will be collected at predefined time points from Day 1 to Day 4 (total duration: max. 4 days).</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A - Single ascending dose (SAD): Terminal half-life (t½).</measure>
    <time_frame>Blood samples for the determination of the PK parameters will be collected at predefined time points from Day 1 to Day 4 (total duration: max. 4 days).</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B - Multiple ascending dose (MAD): AUC during a dosing interval (AUCτ) following the first and the last dose.</measure>
    <time_frame>Blood samples for the determination of the PK parameters will be collected at predefined time points from Day 1 to Day 10 (total duration: max. 10 days).</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B - Multiple ascending dose (MAD): Cmax of the first and the last dosing interval.</measure>
    <time_frame>Blood samples for the determination of the PK parameters will be collected at predefined time points from Day 1 to Day 10 (total duration: max. 10 days).</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B - Multiple ascending dose (MAD): tmax of the first and the last dosing interval.</measure>
    <time_frame>Blood samples for the determination of the PK parameters will be collected at predefined time points from Day 1 to Day 10 (total duration: max. 10 days).</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B - Multiple ascending dose (MAD): t½ after last dose administration.</measure>
    <time_frame>Blood samples for the determination of the PK parameters will be collected at predefined time points from Day 1 to Day 10 (total duration: max. 10 days).</time_frame>
  </secondary_outcome>
  <number_of_arms>12</number_of_arms>
  <enrollment type="Actual">46</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>ACT-1014-6470 single dose (dose level 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Soft capsule for oral administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo single dose (dose level 1)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Soft capsule for oral administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ACT-1014-6470 single dose (dose level 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Soft capsule for oral administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo single dose (dose level 2)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Soft capsule for oral administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ACT-1014-6470 multiple dose (dose level 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Soft capsule for oral administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo multiple dose (dose level 1)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Soft capsule for oral administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ACT-1014-6470 multiple dose (dose level 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Soft capsule for oral administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo multiple dose (dose level 2)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Soft capsule for oral administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ACT-1014-6470 multiple dose (dose level 3)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Soft capsule for oral administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo multiple dose (dose level 3)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Soft capsule for oral administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ACT-1014-6470 multiple dose (dose level 4)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Soft capsule for oral administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo multiple dose (dose level 4)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Soft capsule for oral administration</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ACT-1014-6470</intervention_name>
    <description>Soft capsules for oral administration</description>
    <arm_group_label>ACT-1014-6470 multiple dose (dose level 1)</arm_group_label>
    <arm_group_label>ACT-1014-6470 multiple dose (dose level 2)</arm_group_label>
    <arm_group_label>ACT-1014-6470 multiple dose (dose level 3)</arm_group_label>
    <arm_group_label>ACT-1014-6470 multiple dose (dose level 4)</arm_group_label>
    <arm_group_label>ACT-1014-6470 single dose (dose level 1)</arm_group_label>
    <arm_group_label>ACT-1014-6470 single dose (dose level 2)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Soft capsules for oral administration</description>
    <arm_group_label>Placebo multiple dose (dose level 1)</arm_group_label>
    <arm_group_label>Placebo multiple dose (dose level 2)</arm_group_label>
    <arm_group_label>Placebo multiple dose (dose level 3)</arm_group_label>
    <arm_group_label>Placebo multiple dose (dose level 4)</arm_group_label>
    <arm_group_label>Placebo single dose (dose level 1)</arm_group_label>
    <arm_group_label>Placebo single dose (dose level 2)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        General criteria&#xD;
&#xD;
          -  Signed informed consent prior to any study-mandated procedure.&#xD;
&#xD;
          -  Healthy male subjects (both study parts) and female subjects of nonchildbearing&#xD;
             potential (Part B) aged between 18 and 55 years (inclusive) at Screening.&#xD;
&#xD;
          -  Healthy on the basis of medical history, physical examination, cardiovascular&#xD;
             assessments, and clinical laboratory tests.&#xD;
&#xD;
          -  Male subjects with a partner that might become pregnant must either be vasectomized or&#xD;
             agree to practice adequate contraception from admission to the study site until 3&#xD;
             months after dosing, or the partner must consistently and correctly use (from&#xD;
             Screening, during the entire study, and for at least 3 months after last study&#xD;
             treatment intake) a highly effective method of contraception.&#xD;
&#xD;
        Criteria for Part B only:&#xD;
&#xD;
        • Women of non-childbearing potential must have a negative serum pregnancy test at&#xD;
        Screening and a negative urine pregnancy test on Day-1.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous exposure to the study medication.&#xD;
&#xD;
          -  Any circumstances or conditions, which, in the opinion of the investigator, may affect&#xD;
             full participation in the study or compliance with the protocol.&#xD;
&#xD;
          -  History or clinical evidence of any disease and/or existence of any surgical or&#xD;
             medical condition, which, in the opinion of the investigator, are likely to interfere&#xD;
             with the absorption, distribution, metabolism, or excretion of the study treatment.&#xD;
&#xD;
          -  Relevant bacterial, viral, fungal, or protozoal infection that manifested within the&#xD;
             last 6 weeks prior to Screening and/or ongoing relevant bacterial, viral, fungal, or&#xD;
             protozoal infection, as judged by the investigator, and/or evidence of immune&#xD;
             dysfunction based on laboratory tests at Screening.&#xD;
&#xD;
          -  Any signs or symptoms of active, ongoing infection judged to be clinically relevant by&#xD;
             the investigator (special attention should be given to clinical signs and symptoms&#xD;
             consistent with COVID-19, e.g., fever, dry cough, dyspnea, sore throat, or fatigue).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Parexel International GmbH Klinikum Westend</name>
      <address>
        <city>Berlin</city>
        <zip>14050</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 23, 2020</study_first_submitted>
  <study_first_submitted_qc>October 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 29, 2020</study_first_posted>
  <last_update_submitted>October 7, 2021</last_update_submitted>
  <last_update_submitted_qc>October 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

